News Details

Zoetis Adds Digital Cytology Testing to Vetscan Imagyst™, Its Multi-Purpose Diagnostics Technology Platform

October 5, 2021

First-of-its-kind technology now offers both digital cytology and artificial intelligence (AI) fecal testing in a single platform, furthering company commitment to diagnostics that drive animal care

PARSIPPANY, N.J. – October 5, 2021 – Zoetis today announced its latest innovation in diagnostics with the addition of digital cytology testing to its Vetscan Imagyst™ platform, which was introduced in September 2020. With the launch of digital cytology, Vetscan Imagyst now offers a network of expert remote pathologists in addition to AI technology for fecal testing. As Zoetis continues to develop additional innovative applications for Vetscan Imagyst, it plans to seamlessly integrate even more new capabilities into the platform, helping veterinarians provide the best possible care for dogs and cats.

This latest digital cytology application for Vetscan Imagyst provides rapid access to expert clinical pathologists for the assessment of samples consisting of cells from blood, internal organs, or bodily fluids. This will help enable the fast and minimally invasive diagnosis of cancer, infection, inflammation and more. With fast, accurate review of common cytology specimens, such as fine needle aspirates, Vetscan Imagyst helps veterinarians provide pet owners with same-day diagnosis and treatment, where appropriate. Vetscan Imagyst accelerates the process for clinical pathology review, providing results within hours. Submissions are prepared in-clinic using traditional methods, but submitted digitally, rather than sending physical slides to a laboratory.

“Every veterinarian knows the importance of easy and rapid access to specialists when diagnosing and treating our patients,” said Richard E. Goldstein, DVM, DACVIM (SAIM),

DECVIM-CA, Vice President and Chief Medical Officer, Global Diagnostics at Zoetis. “Now with the new digital cytology solution available from Vetscan Imagyst, we are virtually placing a board-certified, clinical pathologist right ‘down the hall’ from every veterinarian.”

Vetscan Imagyst provides first-of-its-kind technology through its digital cytology capability:

  • Offers multiple applications in a single platform with digital cytology and AI fecal testing results, with the ability to add future applications as they become available
  • Occupies less space with a small in-office footprint and a compact scanner that can be easily added to any clinic
  • Provides veterinary customers access to expert clinical pathologists within the Zoetis network as needed
  • Advances the future of pet care by changing the way and speed at which diagnostic tests can be delivered in clinics

“We are excited to build on the incredible momentum that began with the AI fecal analysis launch,” said Lisa Lee, Senior Vice President and Head of Global Diagnostics at Zoetis. “Vetscan Imagyst has been a significant part of the Zoetis portfolio and continues to evolve to meet diagnostic needs in practices around the world. The unique multi-purpose technology has added immense value to veterinary clinics, facilitating fast, more accurate results, leading to quicker diagnoses and decisions that ultimately strengthen the bond of trust between veterinarians and their clients.”

The addition of digital cytology to Vetscan Imagyst is just one example of Zoetis’ enduring commitment to innovation and relentless drive to meet the unmet needs of its veterinary customers. Vetscan Imagyst is at the forefront of in-clinic diagnostics and will continue to evolve with even more advanced applications that make a meaningful difference for veterinarians, their patients, and pet owners.

Vetscan Imagyst is available in the U.S., UK, Canada, European Union, Australia and New Zealand. Zoetis encourages veterinarians to speak to their Zoetis representatives to learn more about Vetscan Imagyst, or to visit

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. In 2020, Zoetis generated revenue of $6.7 billion with ~11,300 employees. For more information, visit


Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects and expectations regarding products, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at, or on request from Zoetis.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2021 Zoetis Services LLC. All rights reserved. VTS-00494

Multimedia Files: